Physician profile
John Cherian
NPI 1134381593
$13,597.74
in general payments reported to CMS, 2019-2025
51 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,962 · 2020: $1,016 · 2021: $3,941 · 2022: $1,957 · 2023: $2,097 · 2024: $1,292 · 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,652 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,652.26 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $3,079.22 | 2021 | |
| Medtronic, INC. | $1,095.74 | 2021-2025 | Corevalve Evolut R, Endurant Iis, Mycarelink |
| Pfizer INC. | $924.45 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $864.22 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $812.88 | 2019-2025 | Brilinta, Farxiga, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $490.74 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $456.46 | 2020-2025 | Aveir, Gallant, Confirm Rx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $432.89 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $399.31 | 2019-2025 | |
| Amgen INC. | $361.39 | 2019-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $353.34 | 2019-2020 | |
| Novo Nordisk INC | $350.25 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Irhythm Technologies, INC. | $298.00 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Heartflow, INC. | $276.91 | 2023-2025 | Ffrct |
| Abbvie INC. | $266.89 | 2022-2024 | Ubrelvy, Qulipta, Linzess |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.